星空体育官方入口网站网址大全-登录入口官网

#DAPT#

37篇内容 | 1412人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2217377, encodeId=d047221e377fe, content=<a href='/topic/show?id=ab99522007b' target=_blank style='color:#2F92EE;'>#急性冠脉综合征#</a> <a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a> <a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=Eur Heart J-Card Pha：急性冠脉综合征短时间DAPT后P2Y12抑制剂单药治疗效果分析, objectType=article, longId=836695, objectId=208c836695e6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240717/1721181611640_92910.png, objectUrl=/article/show_article.do?id=208c836695e6, replyNumber=0, likeNumber=2, createdTime=2024-07-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=208c836695e6, moduleTitle=Eur Heart J-Card Pha：急性冠脉综合征短时间DAPT后P2Y12抑制剂单药治疗效果分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=208c836695e6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1374365, encodeId=11e513e43659a, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=ESC 2022：15个月随访显示对高出血风险患者采用短期双重抗血小板治疗更为有利（MASTER DAPT研究）, objectType=article, longId=737369, objectId=7ad1e373698d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ad1e373698d, replyNumber=0, likeNumber=88, createdTime=2022-08-31, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ad1e373698d, moduleTitle=ESC 2022：15个月随访显示对高出血风险患者采用短期双重抗血小板治疗更为有利（MASTER DAPT研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7ad1e373698d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374364, encodeId=bc4613e436412, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=双抗期间院外出血风险评估（PRECISE-DAPT score）, objectType=article, longId=300836, objectId=b71930083632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b71930083632, replyNumber=0, likeNumber=41, createdTime=2022-03-17, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b71930083632, moduleTitle=双抗期间院外出血风险评估（PRECISE-DAPT score）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b71930083632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374363, encodeId=738d13e436392, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=武田收购Adaptate Biotherapeutics，以开发针对实体瘤的新型Gamma Delta (γδ) T细胞衔接器疗法, objectType=article, longId=294032, objectId=36af294032f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36af294032f6, replyNumber=0, likeNumber=60, createdTime=2022-01-17, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36af294032f6, moduleTitle=武田收购Adaptate Biotherapeutics，以开发针对实体瘤的新型Gamma Delta (γδ) T细胞衔接器疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=36af294032f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374362, encodeId=aa2113e4362c5, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=JAMA子刊：阿司匹林基础上，替格瑞洛vs氯吡格雷DAPT治疗中风的效果无差！, objectType=article, longId=265003, objectId=1a842650033c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a842650033c, replyNumber=0, likeNumber=62, createdTime=2021-12-14, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a842650033c, moduleTitle=JAMA子刊：阿司匹林基础上，替格瑞洛vs氯吡格雷DAPT治疗中风的效果无差！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1a842650033c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374361, encodeId=6c8913e436164, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=JACC：双抗治疗怕出血？急性冠状动脉综合征DAPT降阶梯治疗的更佳方案来了！, objectType=article, longId=215984, objectId=603a21598498, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=603a21598498, replyNumber=0, likeNumber=60, createdTime=2021-08-20, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=603a21598498, moduleTitle=JACC：双抗治疗怕出血？急性冠状动脉综合征DAPT降阶梯治疗的更佳方案来了！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=603a21598498)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374360, encodeId=3cd513e436025, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=急性心肌梗死患者PCI术后DAPT降阶治疗，不降缺血而降出血风险（TALOS-AMI研究）, objectType=article, longId=214827, objectId=0b7e21482e78, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b7e21482e78, replyNumber=0, likeNumber=78, createdTime=2021-07-27, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b7e21482e78, moduleTitle=急性心肌梗死患者PCI术后DAPT降阶治疗，不降缺血而降出血风险（TALOS-AMI研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0b7e21482e78)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374359, encodeId=236b13e4359c9, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=JAMA子刊：新发TIA和小中风患者发病时收缩压决定90天DAPT治疗获益情况, objectType=article, longId=214766, objectId=e78a214e6649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e78a214e6649, replyNumber=0, likeNumber=68, createdTime=2021-07-26, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e78a214e6649, moduleTitle=JAMA子刊：新发TIA和小中风患者发病时收缩压决定90天DAPT治疗获益情况, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e78a214e6649)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374358, encodeId=2e9813e4358b0, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=DAPT的出血管理策略——冠心病双联抗血小板治疗中国专家共识解读, objectType=article, longId=213596, objectId=a62a2135966f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a62a2135966f, replyNumber=0, likeNumber=111, createdTime=2021-07-02, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a62a2135966f, moduleTitle=DAPT的出血管理策略——冠心病双联抗血小板治疗中国专家共识解读, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a62a2135966f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374357, encodeId=382513e435704, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大, objectType=article, longId=212913, objectId=5ce1212913f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ce1212913f0, replyNumber=0, likeNumber=56, createdTime=2021-06-20, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ce1212913f0, moduleTitle=BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5ce1212913f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374356, encodeId=fbc713e4356af, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=Heart Vessels：冠状动脉支架植入PCI后长期DAPT的患者，从氯吡格雷切换到普拉格雷可使PRU稳定降低, objectType=article, longId=203339, objectId=6dbf20333986, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dbf20333986, replyNumber=0, likeNumber=67, createdTime=2020-11-15, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dbf20333986, moduleTitle=Heart Vessels：冠状动脉支架植入PCI后长期DAPT的患者，从氯吡格雷切换到普拉格雷可使PRU稳定降低, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6dbf20333986)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374355, encodeId=b91413e4355a1, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=EuroIntervention：接受COMBO支架治疗的ACS患者，3个月vs12个月的DAPT结局——REDUCE试验结果, objectType=article, longId=203297, objectId=cfda20329e51, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfda20329e51, replyNumber=0, likeNumber=78, createdTime=2020-11-14, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfda20329e51, moduleTitle=EuroIntervention：接受COMBO支架治疗的ACS患者，3个月vs12个月的DAPT结局——REDUCE试验结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cfda20329e51)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374354, encodeId=215b13e43545f, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=安进联合Adaptive：开发针对新冠病毒的中和性抗体, objectType=article, longId=191369, objectId=eacd1913697a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eacd1913697a, replyNumber=0, likeNumber=89, createdTime=2020-04-05, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eacd1913697a, moduleTitle=安进联合Adaptive：开发针对新冠病毒的中和性抗体, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=eacd1913697a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374353, encodeId=d48113e435375, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=浅谈基于效果反应的适应性随机化 (Response-Adaptive Randomization), objectType=article, longId=183035, objectId=4b911830358a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b911830358a, replyNumber=0, likeNumber=58, createdTime=2019-11-16, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b911830358a, moduleTitle=浅谈基于效果反应的适应性随机化 (Response-Adaptive Randomization), moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4b911830358a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374352, encodeId=7f1513e435243, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=Adaptimmune和Noile-Immune宣布合作，开发增强型SPEAR T细胞肿瘤免疫疗法, objectType=article, longId=178294, objectId=d7c31e8294c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7c31e8294c4, replyNumber=0, likeNumber=70, createdTime=2019-08-30, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7c31e8294c4, moduleTitle=Adaptimmune和Noile-Immune宣布合作，开发增强型SPEAR T细胞肿瘤免疫疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d7c31e8294c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374351, encodeId=1d9f13e4351d3, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=Am J Cardiol: ADAPT-DES研究：高血压合并氯吡格雷抵抗患者远期事件风险高, objectType=article, longId=178280, objectId=73931e828030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73931e828030, replyNumber=0, likeNumber=55, createdTime=2019-08-29, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73931e828030, moduleTitle=Am J Cardiol: ADAPT-DES研究：高血压合并氯吡格雷抵抗患者远期事件风险高, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=73931e828030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374350, encodeId=656913e435068, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=Eur Heart J：MI后接受DAPT的患者采用PPI治疗可使胃肠道出血风险降低, objectType=article, longId=162050, objectId=a75316205062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a75316205062, replyNumber=0, likeNumber=54, createdTime=2019-03-12, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a75316205062, moduleTitle=Eur Heart J：MI后接受DAPT的患者采用PPI治疗可使胃肠道出血风险降低, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a75316205062)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374349, encodeId=3a5913e43496c, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=BMJ：STEMI患者PCI后DAPT无需12个月打对折也可以？, objectType=article, longId=155421, objectId=3ff915542143, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff915542143, replyNumber=0, likeNumber=70, createdTime=2018-12-10, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff915542143, moduleTitle=BMJ：STEMI患者PCI后DAPT无需12个月打对折也可以？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3ff915542143)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374348, encodeId=262b13e434853, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=JACC：房颤合并冠心病患者：DOAC+DAPT降低出血风险效果如何？, objectType=article, longId=153173, objectId=2dfb1531e306, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dfb1531e306, replyNumber=0, likeNumber=87, createdTime=2018-11-11, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dfb1531e306, moduleTitle=JACC：房颤合并冠心病患者：DOAC+DAPT降低出血风险效果如何？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2dfb1531e306)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374347, encodeId=6d9413e434719, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, objectTitle=JACC：双重抗血小板治疗评分（DAPT）遭质疑, objectType=article, longId=147567, objectId=977214e567be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=977214e567be, replyNumber=0, likeNumber=68, createdTime=2018-08-30, rootId=0, userName=mnda, userId=6a8d381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=977214e567be, moduleTitle=JACC：双重抗血小板治疗评分（DAPT）遭质疑, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=977214e567be)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

DAPT

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#急性冠脉综合征# #DAPT# #P2Y12抑制剂#

Eur Heart J-Card Pha：急性冠脉综合征短时间DAPT后P2Y12抑制剂单药治疗效果分析

2024-07-29发表于上海

mnda (审核中...)

前往app查看评论内容

#DAPT#

ESC 2022：15个月随访显示对高出血风险患者采用短期双重抗血小板治疗更为有利（MASTER DAPT研究）

2022-08-31

mnda (审核中...)

前往app查看评论内容

#DAPT#

双抗期间院外出血风险评估（PRECISE-DAPT score）

2022-03-17

mnda (审核中...)

前往app查看评论内容

#DAPT#

武田收购Adaptate Biotherapeutics，以开发针对实体瘤的新型Gamma Delta (γδ) T细胞衔接器疗法

2022-01-17

mnda (审核中...)

前往app查看评论内容

#DAPT#

JAMA子刊：阿司匹林基础上，替格瑞洛vs氯吡格雷DAPT治疗中风的效果无差！

2021-12-14

mnda (审核中...)

前往app查看评论内容

#DAPT#

JACC：双抗治疗怕出血？急性冠状动脉综合征DAPT降阶梯治疗的更佳方案来了！

2021-08-20

mnda (审核中...)

前往app查看评论内容

#DAPT#

急性心肌梗死患者PCI术后DAPT降阶治疗，不降缺血而降出血风险（TALOS-AMI研究）

2021-07-27

mnda (审核中...)

前往app查看评论内容

#DAPT#

JAMA子刊：新发TIA和小中风患者发病时收缩压决定90天DAPT治疗获益情况

2021-07-26

mnda (审核中...)

前往app查看评论内容

#DAPT#

DAPT的出血管理策略——冠心病双联抗血小板治疗中国专家共识解读

2021-07-02

mnda (审核中...)

前往app查看评论内容

#DAPT#

BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大

2021-06-20

mnda (审核中...)

前往app查看评论内容

#DAPT#

Heart Vessels：冠状动脉支架植入PCI后长期DAPT的患者，从氯吡格雷切换到普拉格雷可使PRU稳定降低

2020-11-15

mnda (审核中...)

前往app查看评论内容

#DAPT#

EuroIntervention：接受COMBO支架治疗的ACS患者，3个月vs12个月的DAPT结局——REDUCE试验结果

2020-11-14

mnda (审核中...)

前往app查看评论内容

#DAPT#

安进联合Adaptive：开发针对新冠病毒的中和性抗体

2020-04-05

mnda (审核中...)

前往app查看评论内容

#DAPT#

浅谈基于效果反应的适应性随机化 (Response-Adaptive Randomization)

2019-11-16

mnda (审核中...)

前往app查看评论内容

#DAPT#

Adaptimmune和Noile-Immune宣布合作，开发增强型SPEAR T细胞肿瘤免疫疗法

2019-08-30

mnda (审核中...)

前往app查看评论内容

#DAPT#

Am J Cardiol: ADAPT-DES研究：高血压合并氯吡格雷抵抗患者远期事件风险高

2019-08-29

mnda (审核中...)

前往app查看评论内容

#DAPT#

Eur Heart J：MI后接受DAPT的患者采用PPI治疗可使胃肠道出血风险降低

2019-03-12

mnda (审核中...)

前往app查看评论内容

#DAPT#

BMJ：STEMI患者PCI后DAPT无需12个月打对折也可以？

2018-12-10

mnda (审核中...)

前往app查看评论内容

#DAPT#

JACC：房颤合并冠心病患者：DOAC+DAPT降低出血风险效果如何？

2018-11-11

mnda (审核中...)

前往app查看评论内容

#DAPT#

JACC：双重抗血小板治疗评分（DAPT）遭质疑

2018-08-30

科室
- - 订阅+
  - 更多科室
工具
服务